Effectiveness and Safety of Valsartan in Children Aged 6 to 16Years With Hypertension

Journal of Clinical Hypertension

Volumn 13, Issue 5, 2011, Pages 357-365

  Wells, Thomas ^a   Blumer, Jeffrey ^b   Meyers, Kevin E C ^c   Neto, Jose P R ^d   Meneses, Rejane ^e   Litwin, Mieczysław ^f   Vande Walle, Johan ^g   Solar Yohay, Susan ^h   Shi, Victor ^h   Han, Guangyang ^h  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e HOSPITAL PEQUENO PRÍNCIPE   (Brazil)

^f CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCHLOROTHIAZIDE; METFORMIN; PLACEBO; VALSARTAN;

ACUTE GASTROENTERITIS; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 79955608507     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2011.00432.x     Document Type: Article

References (32)

1. Lurbe E. Hypertension and target organ damage in children and adolescents. J Hypertens. 2007;25:1998-2000.
2. Stabouli S, Kotsis V, Toumanidis S, et al. White-coat and masked hypertension in children: association with target-organ damage. Pediatr Nephrol. 2005;20:1151-1155.
3. Stabouli S, Kotsis V, Zakopoulos N. Ambulatory blood pressure monitoring and target organ damage in pediatrics. J Hypertens. 2007;25:1979-1986.
4. Verberk WJ, Thien T, de Leeuw PW. Masked hypertension, a review of the literature. Blood Press Monit. 2007;12:267-273.
5. Flynn JT. Pediatric hypertension: recent trends and accomplishments, future challenges. Am J Hypertens. 2008;21:605-612.
6. Flynn JT, Daniels SR. Pharmacologic treatment of hypertension in children and adolescents. J Pediatr. 2006;149:746-754.
7. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 suppl):555-576.
8. Seikaly MG. Hypertension in children: an update on treatment strategies. Curr Opin Pediatr. 2007;19:170-177.
9. Flynn JT. Successes and shortcomings of the Food and Drug Modernization Act. Am J Hypertens. 2003;16:889-891.
10. Benjamin DK Jr, Smith PB, Jadhav P, et al. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension. 2008;51:834-840.
11. Wells T, Frame V, Soffer B, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol. 2002;42:870-880.
12. Soffer B, Zhang Z, Miller K, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003;16:795-800.
13. Takai S, Shiota N, Jin D, et al. Functional role of chymase in angiotensin II formation in human vascular tissue. J Cardiovasc Pharmacol. 1998;32:826-833.
14. Richard V, Hurel-Merle S, Scalbert E, et al. Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries. Circulation. 2001;104:750-752.
15. Urata H, Nishimura H, Ganten D, et al. Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases. Blood Press Suppl. 1996;2:22-28.
16. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103:904-912.
17. Flynn JT, Meyers KE, Neto JP, et al. Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5years. Hypertension. 2008;52:222-228.
18. Falkner B, Daniels SR. Summary of the Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Hypertension. 2004;44:387-388.
19. Shahinfar S, Cano F, Soffer BA, et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens. 2005;18:183-190.
20. Flynn JT, Newburger JW, Daniels SR, et al. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145:353-359.
21. Gibbs CR, Beevers DG, Lip GY. The management of hypertensive disease in Black patients. QJM. 1999;92:187-192.
22. Falkner B. Hypertension in children and adolescents: epidemiology and natural history. Pediatr Nephrol. 2010;25:1219-1224.
23. Silverstein DM, Champoux E, Aviles DH, et al. Treatment of primary and secondary hypertension in children. Pediatr Nephrol. 2006;21:820-827.
24. Feld LG, Corey H. Hypertension in childhood. Pediatr Rev. 2007;28:283-298.
25. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52:1749-1757.
26. Sarafidis PA, Bakris GL. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich). 2008;10:130-139.
27. Flynn JT, Mitsnefes M, Pierce C, et al. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension. 2008;52:631-637.
28. Pool JL, Glazer R, Chiang YT, et al. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens. 1999;13:275-281.
29. Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther. 1996;18:797-810.
30. Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 1996;14:1147-1151.
31. Pool J, Oparil S, Hedner T, et al. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther. 1998;20:1106-1114.
32. Hedner T, Oparil S, Rasmussen K, et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens. 1999;12:414-417.